SenzaGen AB (STO:SENZA)

Market Cap	142.21M
Revenue (ttm)	57.70M
Net Income (ttm)	-17.85M
Shares Out	29.50M
EPS (ttm)	-0.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	27,932
Average Volume	27,216
Open	4.830
Previous Close	4.820
Day's Range	4.830 - 5.080
52-Week Range	3.860 - 9.800
Beta	0.32
RSI	46.68
Earnings Date	May 14, 2025

About SenzaGen AB

SenzaGen AB provides non-animal tests for assessing a substance’s allergenicity. The company offers genomic allergen rapid detection (GARD)skin, an in vitro test to identify potential chemical skin sensitizers; GARDpotency, an in vitro add-on test to GARDskin for potency classification; GARDskin Dose-response, an in vitro test for quantitative skin sensitizing potency assessment of chemicals; and GARDair, an in vitro test for identifying chemical respiratory sensitizers, as well as GARDskin medical device, an in vitro skin sensitization testing...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2010
• Employees: 34
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SENZA

Financial Performance

In 2024, SenzaGen AB's revenue was 57.70 million, an increase of 15.69% compared to the previous year's 49.87 million. Losses were -17.85 million, -19.22% less than in 2023.